Proximagen signs collaboration agreement with NINDS

Biotechnology company Proximagen has signed a Collaboration Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) in the US.

Under the terms of the CRADA, NINDS will fully fund and carry out a double-blind cross-over placebo-controlled Phase II clinical trial in patients with epilepsy.

Proximagen, which exclusively owns the worldwide rights to Naluzotan, will use the data from the trial to support the development and commercialisation of the product.